NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to…
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced…
Media Release COPENHAGEN, Denmark; June 3, 2024 Results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate in…
Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO) Lixte Biotechnology Holdings, Inc. PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE)…
Media Release COPENHAGEN, Denmark, and MAINZ, Germany; June 1, 2024 Initial data from the ongoing Phase 2 trial showed a…
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall…
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor…
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma…